Radium-223 dichloride (Xofigo, BAY88-8223) + NAH therapy
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Conditions
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Trial Timeline
Nov 9, 2020 → Oct 12, 2026
NCT ID
NCT04597125About Radium-223 dichloride (Xofigo, BAY88-8223) + NAH therapy
Radium-223 dichloride (Xofigo, BAY88-8223) + NAH therapy is a approved stage product being developed by Bayer for Metastatic Castrate Resistant Prostate Cancer (mCRPC). The current trial status is active. This product is registered under clinical trial identifier NCT04597125. Target conditions include Metastatic Castrate Resistant Prostate Cancer (mCRPC).
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castrate Resistant Prostate Cancer (mCRPC) were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04597125 | Approved | Active |
Competing Products
20 competing products in Metastatic Castrate Resistant Prostate Cancer (mCRPC)